Any feedback?
Please rate this page
(all_enzymes.php)
(0/150)

BRENDA support

1.14.14.32: 17alpha-hydroxyprogesterone deacetylase

This is an abbreviated version!
For detailed information about 17alpha-hydroxyprogesterone deacetylase, go to the full flat file.

Word Map on EC 1.14.14.32

Reaction

17alpha-hydroxypregnenolone
+
[reduced NADPH-hemoprotein reductase]
 +
O2
=
3beta-hydroxyandrost-5-en-17-one
 +
acetate
 +
[oxidized NADPH-hemoprotein reductase]
 +
H2O

Synonyms

17,20 lyase, 17-20 lyase, 17-alpha-hydroxylase/C17-20 lyase, 17-hydroxylase/C17,20-lyase, 17alpha-hydroxylase, 17alpha-hydroxylase-C(17,20)-lyase, 17alpha-hydroxylase-C17,20-lyase, 17alpha-hydroxylase/17,20 lyase, 17alpha-hydroxylase/17,20-lyase, 17alpha-hydroxylase/17,20-lyase cytochrome P450, 17alpha-hydroxylase/C(17,20)-lyase, 17alpha-hydroxylase/C17,20-lyase, 17alpha-hydroxyprogesterone aldolase, 17alpha-hydroxyprogesterone aldolase/17,20-lyase, 17alpha-lyase, Adrenal 17,20-lyase, aldolase, 17alpha-hydroxyprogesterone, C-17,20 lyase, C-17/C-20 lyase, C17(20) lyase, C17,20 lyase, C17,20-lyase, CYP17, CYP17A1, cytochrome P450 17, cytochrome P450 17A1, cytochrome P450 17alpha-hydroxylase/17,20-lyase, cytochrome p450 17alpha-hydroxylase/C(17,20)-lyase, cytochrome P450c17, EC 4.1.2.30, P-45017alpha, P450 17A1, P45017alpha, P450c17, P450c17-I, steroid 17alphahydroxylase/17,20-lyase, Steroid C17(20) lyase

ECTree

     1 Oxidoreductases
         1.14 Acting on paired donors, with incorporation or reduction of molecular oxygen
             1.14.14 With reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen into the other donor
                1.14.14.32 17alpha-hydroxyprogesterone deacetylase

Inhibitors

Inhibitors on EC 1.14.14.32 - 17alpha-hydroxyprogesterone deacetylase

Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
INHIBITOR
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
(17beta)-17-[(5R)-2-(2-chlorophenyl)-4,5-dihydro-1,3-oxazol-5-yl]androst-4-en-3-one
-
-
(17beta)-17-[(5R)-2-(3-chlorophenyl)-4,5-dihydro-1,3-oxazol-5-yl]androst-4-en-3-one
-
-
(17beta)-17-[(5R)-2-(4-bromophenyl)-4,5-dihydro-1,3-oxazol-5-yl]androst-4-en-3-one
-
-
(17beta)-17-[(5R)-2-(4-chlorophenyl)-4,5-dihydro-1,3-oxazol-5-yl]androst-4-en-3-one
-
-
(17beta)-17-[(5R)-2-(4-nitrophenyl)-4,5-dihydro-1,3-oxazol-5-yl]androst-4-en-3-one
-
-
(17beta)-17-[(5R)-2-phenyl-4,5-dihydro-1,3-oxazol-5-yl]androst-4-en-3-one
-
-
(2S,4aR,4bS,6aS,6bR,7S,9aS,10aS,10bS)-4a,6a,7-trimethyl-2,3,4,4a,4b,5,6,6a,6b,7,9,9a,10,10a,10b,11-hexadecahydro-1H-naphtho[2',1':4,5]indeno[2,1-c][1,2]oxazol-2-ol
-
-
(2S,4aR,4bS,6aS,6bS,7S,10aS,10bS)-4a,6a,7-trimethyl-8-(4-methylphenyl)-1,2,3,4,4a,4b,5,6,6a,6b,7,8,10,10a,10b,11-hexadecahydronaphtho[2',1':4,5]indeno[2,1-c]pyrazol-2-ol
-
-
(3beta,17beta)-17-[(5R)-2-(3-chlorophenyl)-4,5-dihydro-1,3-oxazol-5-yl]androst-5-en-3-ol
-
-
(3beta,17beta)-17-[(5R)-2-(4-nitrophenyl)-4,5-dihydro-1,3-oxazol-5-yl]androst-5-en-3-ol
-
-
(3beta,17beta)-17-[2-(4-chlorophenyl)-5,6-dihydro-4H-1,3-oxazin-4-yl]androst-5-en-3-ol
-
decreases enzyme activity by 70% at 50 µM
(5'R)-17beta-[2-(2-chlorophenyl)-4,5-dihydrooxazol-5-yl]androst-5-en-3-one
-
-
(5'R)-17beta-[2-(2-chlorophenyl)-4,5-dihydrooxazol-5-yl]androst-5-en-3beta-ol
-
-
(5'R)-17beta-[2-(3-chlorophenyl)-4,5-dihydrooxazol-5-yl]androst-5-en-3-one
-
-
(5'R)-17beta-[2-(3-chlorophenyl)-4,5-dihydrooxazol-5-yl]androst-5-en-3beta-ol
-
-
(5'R)-17beta-[2-(4-bromophenyl)-4,5-dihydrooxazol-5-yl]androst-5-en-3-one
-
-
(5'R)-17beta-[2-(4-bromophenyl)-4,5-dihydrooxazol-5-yl]androst-5-en-3beta-ol
-
-
(5'R)-17beta-[2-(4-chlorophenyl)-4,5-dihydrooxazol-5-yl]androst-5-en-3-one
-
-
(5'R)-17beta-[2-(4-chlorophenyl)-4,5-dihydrooxazol-5-yl]androst-5-en-3beta-ol
-
-
(5'R)-17beta-[2-(4-fluorophenyl)-4,5-dihydrooxazol-5-yl]androst-5-en-3-one
-
-
(5'R)-17beta-[2-(4-nitrophenyl)-4,5-dihydrooxazol-5-yl]androst-5-en-3-one
-
-
(5'R)-17beta-[2-(4-nitrophenyl)-4,5-dihydrooxazol-5-yl]androst-5-en-3beta-ol
-
-
(5'R)-17beta-[2-phenyl-4,5-dihydrooxazol-5-yl]androst-5-en-3-one
-
-
(S)-orteronel
three times more inhibitory toward the conversion of 17alpha-hydroxypregnenolone to dehydroepiandrosterone than toward the 17alpha-hydroxylation of pregnenolone. The (S)-enantiomer of orteronel is more inhibitory than the (R) enantiomer
1-(3-phenylpropyl)-1H-imidazole
-
-
1-(4-bromobenzyl)-1H-imidazole
-
-
1-(4-iodo-benzyl)-1H-imidazole
-
-
1-(4-phenylbutyl)-1H-imidazole
-
-
1-(5-phenylpentyl)-1H-imidazole
-
-
1-(7-phenyl-heptyl)-1H-imidazole
-
-
1-[3-(4-bromo-phenyl)-propyl]-1H-imidazole
-
-
1-[3-(4-chlorophenyl)-propyl]-1H-imidazole
-
-
1-[3-(4-fluorophenyl)-propyl]-1H-imidazole
-
-
1-[5-(4-bromo-phenyl)-pentyl]-1H-imidazole
-
-
1-[5-(4-chlorophenyl)-pentyl]-1H-imidazole
-
-
1-[5-(4-fluorophenyl)-pentyl]-1H-imidazole
-
-
1-[7-(4-fluorophenyl)-heptyl]-1H-imidazole
-
-
17(E)-picolinyliden-androst-4-en-3beta-ol
-
-
17(E)-picolinyliden-androst-5-en-3beta-ol
-
-
17-(1H-1,2,3-triazol-1-yl)androsta-4,16-dien-3-one
-
VN/85-1
17-(1H-imidazole-1-yl)androsta-4,16-dien-3-one
-
VN/108-1
17beta-(1-p-chlorophenyl-3-pyrazolyl)androst-4-en-3-one
-
91% relative conversion at 0.05 mM
17beta-(1-p-chlorophenyl-3-pyrazolyl)androst-5-en-3beta-ol
-
74% relative conversion at 0.05 mM
17beta-(1-p-chlorophenyl-5-pyrazolyl)androst-4-en-3-one
-
78% relative conversion at 0.05 mM
17beta-(1-p-chlorophenyl-5-pyrazolyl)androst-5-en-3beta-ol
-
-
17beta-(1-p-cyanophenyl-3-pyrazolyl)androst-4-en-3-one
-
34% relative conversion at 0.05 mM
17beta-(1-p-cyanophenyl-3-pyrazolyl)androst-5-en-3beta-ol
-
-
17beta-(1-p-cyanophenyl-5-pyrazolyl)androst-4-en-3-one
-
69% relative conversio at 0.05 mMn
17beta-(1-p-cyanophenyl-5-pyrazolyl)androst-5-en-3beta-ol
-
-
17beta-(1-p-methoxyphenyl-3-pyrazolyl)androst-4-en-3-one
-
54% relative conversion at 0.05 mM
17beta-(1-p-methoxyphenyl-3-pyrazolyl)androst-5-en-3beta-ol
-
95% relative conversion at 0.05 mM
17beta-(1-p-methoxyphenyl-5-pyrazolyl)androst-4-en-3-one
-
91% relative conversion at 0.05 mM
17beta-(1-p-methoxyphenyl-5-pyrazolyl)androst-5-en-3beta-ol
-
-
17beta-(1-p-tolyl-3-pyrazolyl)androst-4-en-3-one
-
92% relative conversion at 0.05 mM
17beta-(1-p-tolyl-5-pyrazolyl)androst-4-en-3-one
-
86% relative conversion at 0.05 mM
17beta-(1-p-tolyl-5-pyrazolyl)androst-5-en-3beta-ol
-
89% relative conversion at 0.05 mM
17beta-(1-p-tolylphenyl-3-pyrazolyl)androst-5-en-3beta-
-
-
17beta-(1-p-tolylphenyl-3-pyrazolyl)androst-5-en-3beta-ol
-
93% relative conversion at 0.05 mM
17beta-(1-p-tolylphenyl-5-pyrazolyl)androst-5-en-3beta-
-
-
17beta-(1-phenyl-3-pyrazolyl)androst-4-en-3-one
-
86% relative conversion at 0.05 mM
17beta-(1-phenyl-3-pyrazolyl)androst-5-en-3beta-ol
-
65% relative conversion at 0.05 mM
17beta-(1-phenyl-5-pyrazolyl)androst-4-en-3-one
-
87% relative conversion at 0.05 mM
17beta-(1-phenyl-5-pyrazolyl)androst-5-en-3beta-ol
-
92% relative conversion at 0.05 mM
17beta-(2-oxazolidon-5-yl)-androst-4-en-3-one
-
-
17beta-(2-oxazolidon-5-yl)androst-5-en-3beta-ol
-
-
17beta-[3-(N-3,5-dimethylphenyl)-2-oxazolidon-5-yl]androst-4-en-3-one
-
-
17beta-[3-(N-3,5-dimethylphenyl)-2-oxazolidon-5-yl]androst-5-en-3beta-ol
-
-
17beta-[3-(N-4-bromophenyl)-2-oxazolidon-5-yl]androst-4-en-3-one
-
-
17beta-[3-(N-4-bromophenyl)-2-oxazolidon-5-yl]androst-5-en-3beta-ol
-
-
17beta-[3-(N-4-chlorophenyl)-2-oxazolidon-5-yl]androst-4-en-3-one
-
-
17beta-[3-(N-4-chlorophenyl)-2-oxazolidon-5-yl]androst-5-en-3beta-ol
-
-
17beta-[3-(N-4-fluorophenyl)-2-oxazolidon-5-yl]androst-4-en-3-one
-
-
17beta-[3-(N-4-fluorophenyl)-2-oxazolidon-5-yl]androst-5-en-3beta-ol
-
-
17beta-[3-(N-4-methoxyphenyl)-2-oxazolidon-5-yl]androst-4-en-3-one
-
-
17beta-[3-(N-4-methoxyphenyl)-2-oxazolidon-5-yl]androst-5-en-3beta-ol
-
-
17beta-[3-(N-phenyl)-2-oxazolidon-5-yl]androst-4-en-3-one
-
-
17beta-[3-(N-phenyl)-2-oxazolidon-5-yl]androst-5-en-3beta-ol
-
-
2'-[[(E)-3beta-hydroxyandrost-5-en-17-ylidene]methyl]-4',4'-dimethyl-4',5'-dihydro-1',3'-oxazole
-
-
2'-[[(E)-3beta-hydroxyandrost-5-en-17-ylidene]methyl]-4',5'-dihydro-1',3'-oxazole
-
-
2-fluoro-4-[5-(pyridin-4-yl)-5,6,7,8-tetrahydronaphthalen-2-yl]phenol
-
-
2-fluoro-4-[5-(pyridin-4-yl)-7,8-dihydronaphthalen-2-yl]phenol
-
-
3-[5-(4-fluorophenyl)-2,3-dihydro-1H-inden-1-yl]pyridine
-
-
3-[6-(4-fluorophenyl)-1H-inden-3-yl]pyridine
-
-
3beta-acetoxy-21-chloropregn-5-ene-20beta-N-phenylurethane
-
-
3beta-acetoxy-5alpha,6beta,17alpha,21-tetrabromo-pregnane-20-one
-
-
3beta-hydroxy-17-(1H-1,2,3-triazol-1-yl)androsta-5,16-diene
-
VN/87-1
3beta-hydroxy-17-(1H-benzimidazol-1-yl)androsta-5,16-diene
-
VN/124-1
3beta-hydroxy-17-(1H-benzimidazole-1-yl)androsta-5,16-diene
-
VN/124-1
3beta-hydroxy-17-(50-[30-methyl]-10,20,40-oxadiazolyl)androst-5,16-diene
4-(1H-imidazol-1-ylmethyl)-7-[(3-methylbenzyl)oxy]-2H-chromen-2-one
-
-
4-(1H-imidazol-1-ylmethyl)-7-[[3-(trifluoromethyl)benzyl]oxy]-2Hchromen-2-one
-
-
4-(1H-imidazol-1-ylmethyl)phenyl 4-(trifluoromethyl)benzenesulfonate
-
-
4-(1H-imidazol-1-ylmethyl)phenyl 4-bromobenzenesulfonate
-
-
4-(1H-imidazol-1-ylmethyl)phenyl 4-chlorobenzenesulfonate
-
-
4-(1H-imidazol-1-ylmethyl)phenyl 4-fluorobenzenesulfonate
-
-
4-(1H-imidazol-1-ylmethyl)phenyl 4-iodobenzenesulfonate
-
-
4-(1H-imidazol-1-ylmethyl)phenyl 4-methoxybenzenesulfonate
-
-
4-(1H-imidazol-1-ylmethyl)phenyl 4-nitrobenzenesulfonate
-
-
4-(1H-imidazol-1-ylmethylphenyl)-4-toluenesulfonate
-
-
4-iodobenzyl imidazole
-
-
4-nonylphenol
-
strong inhibitory effect at 0.1 mM
4-[5-(4-fluorophenyl)-2,3-dihydro-1H-inden-1-yl]pyridine
-
-
4-[5-(pyridin-4-yl)-5,6,7,8-tetrahydronaphthalen-2-yl]benzene-1,2-diol
-
-
4-[5-(pyridin-4-yl)-7,8-dihydronaphthalen-2-yl]benzene-1,2-diol
-
-
4-[6-(3,4-difluorophenyl)-1,2,3,4-tetrahydronaphthalen-1-yl]pyridine
-
-
4-[6-(3,4-difluorophenyl)-3,4-dihydronaphthalen-1-yl]pyridine
-
-
4-[6-(4-fluorophenyl)-1,2,3,4-tetrahydronaphthalen-1-yl]pyridine
-
-
4-[6-(4-fluorophenyl)-1H-inden-3-yl]pyridine
-
-
4-[6-(4-fluorophenyl)-3,4-dihydronaphthalen-1-yl]pyridine
-
-
4-[6-(4-methoxyphenyl)-1H-inden-3-yl]pyridine
-
-
5-(4-fluorophenyl)-1-(pyridin-3-yl)-2,3-dihydro-1H-inden-1-ol
-
-
6-(3,4-difluorophenyl)-1-(pyridin-3-yl)-1,2,3,4-tetrahydronaphthalen-1-ol
-
-
6-(3-fluoro-4-methoxyphenyl)-1-(pyridin-3-yl)-1,2,3,4-tetrahydronaphthalen-1-ol
-
-
7-[(3-chlorobenzyl)oxy]-4-(1H-imidazol-1-ylmethyl)-2H-chromen-2-one
-
-
7-[(3-fluorobenzyl)oxy]-4-(1H-imidazol-1-ylmethyl)-2H-chromen-2-one
-
-
abiraterone
abiraterone acetate
-
bitertanol
-
cyclopregnenolone
-
i.e. 3alpha5-cyclo-6beta-methoxy-5alpha-pregnane-20-one
diethylstilbestrol
-
-
dioctyltin chloride
-
estradiol-17beta
-
concentration of 0.3 mM both, testicular and male duodenal enzyme with exogenous 17alpha-hydroxyprogesterone as substrate are inhibited by 30-40%
fluconazole
-
flusilazole
Insulin
-
acute and selective
-
ketoconazole
methylmercury
-
-
O-3beta-acetoxyandrost-5,16-diene-17-acyl-p-methoxybenzamidoxime
-
compound displays in vitro cytotoxic activity against HeLa cells, MCF-7 cells, A-2780 cells and A-431 cells which are higher than or comparable to that of the reference cisplatin
O-3beta-acetoxyandrost-5,16-diene-17-acylacetamidoxime
-
compound displays in vitro cytotoxic activity against HeLa cells, MCF-7 cells, A-2780 cells and A-431 cells which are higher than or comparable to that of the reference cisplatin
Promegestone
-
competitive
Propiconazole
-
SU10603
tebuconazole
tetrabromobisphenol A
-
-
TOK-001
-
-
triadimenol
-
VT-464
-
selective suppression of androgen synthesis through CYP17 lyase inhibition
additional information
-